STOCK TITAN

Aravive Inc - ARAV STOCK NEWS

Welcome to our dedicated news page for Aravive (Ticker: ARAV), a resource for investors and traders seeking the latest updates and insights on Aravive.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aravive's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aravive's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.23%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.53%
Tags
conferences
Aravive Inc

Nasdaq:ARAV

ARAV Rankings

ARAV Stock Data

2.95M
45.08M
38.69%
8.21%
1.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Houston

About ARAV

versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.